Clinical predictors of treatment outcome in adult Tuberculous Meningitis patients at the Kundiawa General Hospital

Stanley Aiwara; Isi H. Kevau; David Linge; Izzard Aglua

doi:10.1101/2022.09.03.22279565

Abstract

Background Tuberculous meningitis is the most severe form of extrapulmonary TB and accounted for 5 % of 10 million TB cases globally in the WHO 2018 report, with mortality as high as 19.35% in children and 30% in adults. Clinicians in resource-poor settings are often challenged with limited diagnostic and therapeutic options for optimal patient care, and often rely on clinical parameters for diagnosis, treatment, monitoring and outcome prediction.

Aim This study was done to identify potential clinical predictors of i) length of in-hospital stay, and ii) death or discharge at 28 days, amongst Melanesian adults with TB meningitis at the Kundiawa General Hospital in Simbu Province of Papua New Guinea.

Method A retrospective observational study was conducted on 65 Melanesian adults with TB meningitis at the Kundiawa General Hospital in Simbu province between 2015 and 2019.

Result High case fatality (48%) and mortality rates (2.22 per 100,000 per year) for TB Meningitis in this study. Even higher case fatality of 90.9% with HIV co-infection. Parameters associated with higher 28-day mortality included admission GCS (P=0.039, 95% CI), HIV-TBM co-infection (P=0.049, 95% CI), positive fluid balance 24 hours after admission (P=0.061, 95% CI) and male gender (P=0.057, 95% CI).

Conclusion Study showed high case fatality (48%) and mortality rates (2.22 per 100,000 per year) for adult TB Meningitis, with even higher case fatality (90.9%) for HIV-TB co-infection. Admission GCS, positive fluid balance 24 hours after admission, HIV-TB co-infection and male gender were associated with higher 28-day mortality.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical consideration and approval was granted by the interim Institutional Review Committee of the SiPHA-Clinical Research Center.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes